Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
British pharmaceutical giant AstraZeneca said net profit jumped 18% in 2024. https://t.co/GjY8yb5z4s
AstraZeneca announced a 38% jump in annual pretax profits, driven by strong sales of its cancer and immunology treatments. https://t.co/396fhLdov8
$AZN Guidance: "Today, we issued guidance for 2025 and expect total revenue to increase by a high single-digit percentage and core EPS to increase by low double-digit percentage. We anticipate our strong growth momentum to continue in 2025, more than offsetting the headwinds… https://t.co/Xtyi8VL5ET
AstraZeneca reported a net profit increase of 18% for the year 2024, amounting to €6.796 billion, driven primarily by robust sales in its oncology and immunology divisions. The company also indicated a 21% rise in revenues and proposed a higher-than-expected dividend, with plans to further increase the dividend during the second half of 2025. AstraZeneca's guidance for 2025 anticipates total revenue growth in the high single digits and core earnings per share growth in the low double digits, reflecting ongoing strong growth momentum despite potential market challenges.